MFM Ltd: A statement from Roger Waters on the controversy over his Berlin Concert

Share

Frankfurt. “My recent performance in Berlin has attracted bad faith attacks from those who want to smear and silence me because they disagree with my political views and moral principles.

The elements of my performance that have been questioned are quite clearly a statement in opposition to fascism, injustice, and bigotry in all its forms. Attempts to portray those elements as something else are disingenuous and politically motivated. The depiction of an unhinged fascist demagogue has been a feature of my shows since Pink Floyd’s “The Wall” in 1980.

I have spent my entire life speaking out against authoritarianism and oppression wherever I see it. When I was a child after the war, the name of Anne Frank was often spoken in our house, she became a permanent reminder of what happens when fascism is left unchecked. My parents fought the Nazis in World War II, with my father paying the ultimate price.

Regardless of the consequences of the attacks against me, I will continue to condemn injustice and all those who perpetrate it.”

Publisher:

MFM Ltd.
on behalf of Mr George Roger Waters

 

Press Contact:

HÖCKER Rechtsanwälte PartGmbB

Rechtsanwalt Prof. Dr. Ralf Höcker

Rechtsanwalt Michael Fengler

E-Mail:    contact@hoecker.eu

Tel:        +49(0)221-93319-10

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Biomay Launches FDA-Grade CRISPR/Cas9 Nuclease for Off-the-Shelf Purchase9.5.2025 12:00:00 CEST | Press release

(Vienna, Austria) Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its off-the-shelf product portfolio for genome-editing applications. Clients purchasing Biomay´s Cas9 will benefit from the company´s unparalleled track record and expertise as a market-registered GMP-manufacturer of the nuclease. Biomay is the FDA-approved manufacturer of recombinant Cas9 as the essential component of CASGEVY®, the very first CRISPR genome editing product on the market. Biomay’s Cas9 (internal code “BMC9”) is based on the classical wild-type Cas9 nuclease from Streptococcus pyogenes. The Cas9 manufacturing process has been de novo developed, GMP-implemented and PPQ-validated by Biomay. GMP and RUO manufacturing is performed by fermentation with E. coli and by purification with chromatographic methods. By quality control with a comprehensive set of validated analytical assays, the consistent

mAInthink GmbH: Technological Breakthrough: Hallucination-Free Superintelligence Achieves 99.99% Strategic Accuracy – Germany Gains Permanent Strategic Superiority9.5.2025 10:57:00 CEST | Press release

Worms, May 9, 2025 – The mAInthink GmbH has achieved a technological breakthrough that redefines the future of strategic decision-making: With the development of StratePlan, a hallucination-free superintelligence delivering verified 99.99% strategic accuracy, Germany secures permanent technological, economic, and geopolitical superiority – operationally deployable and scientifically validated.

HEIDELBERG/Amperfied presents new DC fast charging solution with comprehensive range of services: Focus on dynamic power distribution and high availability7.5.2025 08:56:00 CEST | Press release

Offer is aimed at the increasing demand from charging parks, logistics depots and haulage fleets Amperfied addresses demand for fast charging system solutions with new DC product and performance-based offering DC becomes part of an availability-based operating hours model Modular technology for optimum utilization of the charging system and small footprint Debut at the Power2Drive 2025 Amperfied GmbH, a subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), is entering the market for fast charging solutions complete with a comprehensive range of services. At the Power2Drive trade fair in Munich, the company will unveil its modular DC fast charging solution called Amperfied Dynamic DC, which focuses on availability and efficiency. The offering is aimed primarily at the growing demand from charging parks, logistics depots and haulage fleets for high-availability system solutions. This is because only with fast and functional charge points can charging infrastructure operators (CPOs)

HEIDELBERG holds its ground in a difficult market environment in FY 2024/25 - targets achieved, significant increase in incoming orders compared to previous year6.5.2025 08:52:59 CEST | Press release

Sales and adjusted EBITDA margin at previous year's level according to preliminary figures Free cash flow excluding special items clearly positive at around € 50 million Rising order intake compared to previous year lays the foundation for a good start to FY 2025/26 Additional, positive order impetus expected from China Print trade fair in May Adjusted EBITDA margin to rise to around 8 percent in FY 2025/26

eM Client version 10.3 adds features familiar from Postbox5.5.2025 13:32:56 CEST | Press release

Prague – 05.05.2025 - The Czech company eM Client has launched a new version of its eponymous email application, positioning their software as the primary rival to Microsoft Outlook in the email app market. The most recent release, version 10.3, also incorporates the most popular features from Postbox, an email application developed by Postbox Inc., which has ceased operations and was acquired by eM Client in 2024.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye